We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-11.05%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.3B
AUM Growth
-$460M
(-17%)
Cap. Flow
-$148M
Cap. Flow
% of AUM
-6.44%
Top 10 Holdings %
Top 10 Hldgs %
58.87%
Holding
47
New
10
Increased
12
Reduced
5
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SEM
Select Medical
SEM
|
+$71.5M |
| 2 |
Tenet Healthcare
THC
|
+$67.9M |
| 3 |
Dentsply Sirona
XRAY
|
+$50.5M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$34.9M |
| 5 |
Myriad Genetics
MYGN
|
+$31.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$149M |
| 2 |
Merck
MRK
|
+$123M |
| 3 |
Universal Health Services
UHS
|
+$107M |
| 4 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$85.8M |
| 5 |
Medtronic
MDT
|
+$55.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.67% |
| 2 | Technology | 2.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
| $20.7M | 0.9% |
2,750,000
| – | – |
|
27
Inogen
INGN
$138M
| $19.9M | 0.87% |
825,000
+75,000
| +10% | +$1.99M |
|
28
Collegium Pharmaceutical
COLL
$711M
| $18.6M | 0.81% |
1,050,000
| – | – |
|
29
Quanterix
QTRX
$129M
| $18.5M | 0.8% |
+1,141,700
| New | +$23.5M |
|
|
CSII
30
DELISTED
Cardiovascular Systems, Inc.
CSII
| $13.5M | 0.59% |
+940,400
| New | +$16.3M |
|
|
CANO
31
DELISTED
Cano Health, Inc.
CANO
| $13.1M | 0.57% |
+30,000
| New | +$15.6M |
|
32
Puma Biotechnology
PBYI
$477M
| $12.1M | 0.52% |
4,235,000
+235,000
| +6% | +$584K |
|
|
EXAS
33
DELISTED
Exact Sciences
EXAS
| $11.8M | 0.51% |
+300,000
| New | +$16M |
|
34
OraSure Technologies
OSUR
$239M
| $11.5M | 0.5% |
4,250,000
| – | – |
|
|
NSTG
35
DELISTED
NanoString Technologies, Inc.
NSTG
| $10.8M | 0.47% |
+850,000
| New | +$15.8M |
|
36
Zymeworks
ZYME
$1.86B
| $10.6M | 0.46% |
2,000,000
| – | – |
|
37
Glaukos
GKOS
$10.1B
| $8.49M | 0.37% |
187,022
| – | – |
|
38
Pacific Biosciences
PACB
$417M
| $1.88M | 0.08% |
+424,600
| New | +$2.58M |
|
|
SDC
39
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $1.04M | 0.05% |
1,000,000
| – | – |
|
|
TSVT
40
DELISTED
2seventy bio
TSVT
| $642K | 0.03% |
+48,600
| New | +$662K |
|
|
41
Gilead Sciences
GILD
$181B
| – | – |
-2,500,000
| Closed | -$149M |
|
42
GSK
GSK
$100B
| – | – |
-800,000
| Closed | -$43.6M |
|
|
43
Medtronic
MDT
$120B
| – | – |
-500,000
| Closed | -$55.5M |
|
|
44
Merck
MRK
$355B
| – | – |
-1,500,000
| Closed | -$123M |
|
45
Neurocrine Biosciences
NBIX
$15.2B
| – | – |
-300,000
| Closed | -$28.1M |
|
46
Nektar Therapeutics
NKTR
$2.28B
| – | – |
-266,667
| Closed | -$21.6M |
|
|
RDUS
47
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-262,900
| Closed | -$2.32M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Camber Capital Management held 47 positions worth $2.3B, down 17% from $2.76B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Camber Capital Management withdrew a net $148M in Q2 2022, closing 7 positions and reducing 5 holdings. Its most notable exit was Gilead Sciences, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Technology.
Against the trend, Camber Capital Management opened a new position in Dentsply Sirona worth $44.7M.
- Camber Capital Management's largest Q2 2022 buy was Dentsply Sirona: 1,250,000 shares worth $44.7M.
- Camber Capital Management added most to Select Medical in Q2 2022, an estimated $71.5M increase.
- Camber Capital Management's biggest Q2 2022 reduction was Universal Health Services, cutting an estimated $107M.
- Camber Capital Management fully exited Gilead Sciences in Q2 2022, selling an estimated $149M.
- Camber Capital Management's ten largest holdings make up 59% of its $2.3B portfolio in Q2 2022.
- Camber Capital Management opened 10 new positions and closed 7 in Q2 2022.
- Camber Capital Management's portfolio value fell 17% quarter-over-quarter to $2.3B.
Based on Camber Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.